Mostrar el registro sencillo del ítem

dc.contributor.authorMartín Blázquez, Ariadna
dc.contributor.authorJiménez Luna, Cristina 
dc.contributor.authorDíaz, Caridad
dc.contributor.authorMartínez-Galán, Joaquina
dc.contributor.authorPrados Salazar, José Carlos 
dc.contributor.authorVicente, Francisca
dc.contributor.authorMelguizo Alonso, Consolación 
dc.contributor.authorGenilloud Rodríguez, Olga
dc.contributor.authorPérez del Palacio, José
dc.contributor.authorCaba Pérez, Octavio 
dc.date.accessioned2020-06-12T12:47:18Z
dc.date.available2020-06-12T12:47:18Z
dc.date.issued2020-04
dc.identifier.citationMartín-Blázquez, A., Jiménez-Luna, C., Díaz, C., Martínez-Galán, J., Prados, J., Vicente, F., ... & Caba, O. (2020). Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Cancers, 12(4), 1002. [doi:10.3390/cancers12041002]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/62454
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection remains the only curative treatment. However, fewer than 20% of patients are candidates for surgery at the time of presentation. Hence, there is a critical need to identify diagnostic biomarkers with potential clinical utility in this pathology. In this context, metabolomics could be a powerful tool to search for new robust biomarkers. Comparative metabolomic profiling was performed in serum samples from 59 unresectable PDAC patients and 60 healthy controls. Samples were analyzed by using an untargeted metabolomics workflow based on liquid chromatography, coupled to high-resolution mass spectrometry in positive and negative electrospray ionization modes. Univariate and multivariate analysis allowed the identification of potential candidates that were significantly altered in PDAC patients. A panel of nine candidates yielded excellent diagnostic capacities. Pathway analysis revealed four altered pathways in our patients. This study shows the potential of liquid chromatography coupled to high-resolution mass spectrometry as a diagnostic tool for PDAC. Furthermore, it identified novel robust biomarkers with excellent diagnostic capacities.es_ES
dc.description.sponsorshipThis research was funded by JUNTA DE ANDALUCIA, grant number PIN-0474-2016 and PC-0549-2017 and INSTITUTO DE SALUD CARLOS III (FEDER), grant number DTS17/00081.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMetabolomicses_ES
dc.subjectPancreatic ductal adenocarcinomaes_ES
dc.subjectReverse-phase liquid chromatographyes_ES
dc.subjectBiomarkeres_ES
dc.subjectDiagnosis es_ES
dc.titleDiscovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomicses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doidoi:10.3390/cancers12041002


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España